What's New
Pregabalin is now fully fundedFebruary 12, 2019
Pregabalin is a gabapentinoid that is now fully funded and indicated as an option for patients with neuropathic pain, as well as focal seizures and generalised anxiety (unlicensed). Pregabalin may offer advantages over gabapentin in patients where adherence to a three-times-daily regimen is problematic or where gastrointestinal absorption may be impaired. The efficacy of gabapentinoids […]
New classes of drugs fully funded from 1st Oct 2018: vildagliptin and sacubitril/valsartanOctober 3, 2018
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes. See BPAC article for further information. Sacubitril/valsartan is approved for the treatment of symptomatic chronic heart failure with LVEF ≤40%. Sacubitril is a neprilysin inhibitor (inhibits breakdown of natriuretic peptides increasing diuresis, natriuresis, and vasodilation) and valsartan is an angiotensin-2 […]